Takeda Just Ghosted Denali on a $150M Brain Drug Deal

Why Takeda Walked Away

Takeda isn't abandoning neuroscience entirely, at least not on paper. The company still lists neurodegeneration, rare neurology, and orexin science as core focus areas. But actions speak louder than pipeline slides.

On March 25, 2026, Takeda's board approved a massive restructuring designed to deliver more than $1.25 billion in annualized savings by 2028. The plan involves flattening management layers, automating tasks with AI, and streamlining corporate functions. Translation: cut costs everywhere and double down on the programs most likely to pay off.

This isn't Takeda's first exit from Denali's pipeline, either. A previous collaboration asset called DNL919, a TREM2 agonist aimed at Alzheimer's, was placed on FDA clinical hold in January 2022, which was later lifted. The program was ultimately discontinued in August 2023 after Phase 1 data revealed a frustratingly narrow therapeutic window. That earlier failure likely colored Takeda's appetite for continued CNS risk.

With the DNL593 termination, all remaining collaborations between the two companies are now over. Eight years, and nothing to show for it.

Denali's Not Panicking (Yet)

To Denali's credit, the company seems unfazed. CEO Ryan Watts expressed confidence in the science behind DNL593 and committed to advancing the program independently.

The numbers support that confidence, at least for now. Denali has a significant cash runway. The ongoing Phase 1/2 trial for DNL593 has already completed enrollment with 40 patients, and data is expected by the end of 2026. No new money needs to be raised, no desperate partnering deals need to happen tomorrow.

Wall Street seemed to agree. Denali's stock actually rose on the day of the announcement. Investors apparently viewed the clean exit (no termination fees, no messy financial obligations) as manageable rather than catastrophic.

But analysts aren't unanimous. Losing Takeda means losing its funding, its regulatory expertise, and its 50/50 commercialization rights in the U.S. If the Phase 1/2 data looks promising and Denali needs to run a larger, more expensive trial, that cash pile will shrink fast without a partner to share the bill.

A Bigger Trend Is Lurking Here

Takeda isn't the only big pharma company getting cold feet about brain diseases. The last two years have seen a quiet but unmistakable pattern.

Roche ended its Alzheimer's collaboration with UCB and returned two failed assets to AC Immune. Johnson & Johnson killed programs targeting Alzheimer's and Parkinson's. AstraZeneca shut down its entire neuroscience research group, pulling experimental drugs for Alzheimer's, migraine, and pain. Sage Therapeutics halted a Parkinson's program after a mid-stage failure. Otsuka walked away from a Phase III Alzheimer's agitation drug.

That's a lot of exits.

Analysts at Mizuho have pushed back on the "mass retreat" narrative, arguing these are individual clinical failures rather than a coordinated industry strategy. And they have a point: Sanofi acquired Vigil Neuroscience in May 2025, adding a TREM2-targeting Alzheimer's asset to its pipeline after a $40 million strategic investment the year before. The overall Alzheimer's development pipeline actually expanded in 2025 compared to the prior year.

So it's not that pharma has given up on the brain. It's more like natural selection: companies are getting ruthless about which bets survive.

What Happens Next

The immediate future for DNL593 comes down to one thing: data. Denali expects Phase 1/2 results, including biomarker readouts, by the end of this year. If the drug shows meaningful progranulin delivery and biological activity in patient brains, the partnership offers will come knocking.

If the data disappoints? Well, Denali still has a validated drug delivery platform and an FDA-approved product in Avlayah. The company isn't a one-trick pony.

For Takeda, the question is whether its restructuring math actually works. Cutting $1.25 billion in costs only makes sense if you're reinvesting that money into programs that deliver. Neuroscience was supposed to be one of those areas. Walking away from a Phase 1/2 asset with no safety concerns suggests the company either lost confidence in FTD-GRN as a commercial opportunity or decided rare dementia wasn't worth the risk relative to other pipeline bets.

Either way, Denali is on its own now. For a company that just got its first drug approved, that might not be the worst thing in the world.

An AI Just Designed an Opioid Addiction Drug. No Human Chemist Required.

A computer just designed a new opioid addiction drug that doesn't touch opioid receptors at all. GATC Health's AI-generated candidate is heading into human trials, and it could signal a turning point for a field that's been stuck for decades.